Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H23N3O2.ClH |
| Molecular Weight | 313.823 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN(CC)CCNC(=O)C1=CC=C(NC(C)=O)C=C1
InChI
InChIKey=IYEWBJUCJHKLHD-UHFFFAOYSA-N
InChI=1S/C15H23N3O2.ClH/c1-4-18(5-2)11-10-16-15(20)13-6-8-14(9-7-13)17-12(3)19;/h6-9H,4-5,10-11H2,1-3H3,(H,16,20)(H,17,19);1H
| Molecular Formula | C15H23N3O2 |
| Molecular Weight | 277.362 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Acecainide (N-acetylprocainamide), the N-acetylated metabolite of procainamide, is a Class III antiarrhythmic agent. Acecainide exerts cardiac anticholinergic effect. It elicits smooth muscle relaxation mainly through the activation of plasma membrane K+ channels. Acecainide markedly reduced premature ventricular beats and prevented induction of ventricular tachycardia. Acecainide appears to offer advantages over procainamide, particularly with respect to the reduced formation of antinuclear antibodies. Acecainide development has been discontinued.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Development of multifocal atrial tachycardia in a patient using aminophylline -A case report-. | 2010-12 |
|
| Overview of therapeutic drug monitoring. | 2009-03 |
|
| The prince and the pauper. A tale of anticancer targeted agents. | 2008-10-23 |
|
| Drug therapy considerations in arrhythmias in children. | 2008-08-01 |
|
| Procainamide, but not N-acetylprocainamide, induces protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis. | 2008-05 |
|
| Clinical review: Drug metabolism and nonrenal clearance in acute kidney injury. | 2008 |
|
| Effect of drugs on defibrillation capacity. | 2008 |
|
| Drug-herb interaction: effect of St John's wort on bioavailability and metabolism of procainamide in mice. | 2007-07 |
|
| Simultaneous determination of procaine and para-aminobenzoic acid by LC-MS/MS method. | 2007-03-01 |
|
| Therapeutic levels of intravenous procainamide in neonates: a retrospective assessment. | 2006-12 |
|
| Application of a generic physiologically based pharmacokinetic model to the estimation of xenobiotic levels in human plasma. | 2006-01 |
|
| St. John's wort does not interfere with therapeutic drug monitoring of 12 commonly monitored drugs using immunoassays. | 2006 |
|
| Class I antiarrhythmics inhibit Na+ absorption and Cl- secretion in rabbit descending colon epithelium. | 2005-06 |
|
| High-throughput solution-based medicinal library screening against human serum albumin. | 2005-03-01 |
|
| Massive cell vacuolization induced by organic amines such as procainamide. | 2004-07 |
|
| cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. | 2002-07 |
|
| N-substituted benzamides inhibit nuclear factor-kappaB and nuclear factor of activated T cells activity while inducing activator protein 1 activity in T lymphocytes. | 2001-08 |
|
| Quantitative estimation of renal clearance of N-acetylprocainamide in rats with various experimental acute renal failure. | 2001-06 |
|
| Role of K+ channels in N-acetylprocainamide-induced relaxation of bovine tracheal smooth muscle. | 2001-03-09 |
|
| Study of procainamide hapten-specific antibodies in rabbits and humans. | 1993-11 |
|
| Torsades de pointes due to n-acetylprocainamide. | 1985-07 |
|
| Torsade de pointes associated with elevated N-acetylprocainamide levels. | 1985-02 |
|
| Polymorphic ventricular tachycardia and ventricular fibrillation due to N-acetyl procainamide. | 1985-01-01 |
|
| Cumulation of N-acetylprocainamide, an active metabolite of procainamide, in patients with impaired renal function. | 1977-07 |
|
| Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure. | 1976-11-01 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:57:58 GMT 2025
by
admin
on
Mon Mar 31 17:57:58 GMT 2025
|
| Record UNII |
B9K738KX14
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C47793
Created by
admin on Mon Mar 31 17:57:58 GMT 2025 , Edited by admin on Mon Mar 31 17:57:58 GMT 2025
|
||
|
NCI_THESAURUS |
C93038
Created by
admin on Mon Mar 31 17:57:58 GMT 2025 , Edited by admin on Mon Mar 31 17:57:58 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
B9K738KX14
Created by
admin on Mon Mar 31 17:57:58 GMT 2025 , Edited by admin on Mon Mar 31 17:57:58 GMT 2025
|
PRIMARY | |||
|
34118-92-8
Created by
admin on Mon Mar 31 17:57:58 GMT 2025 , Edited by admin on Mon Mar 31 17:57:58 GMT 2025
|
PRIMARY | |||
|
m1291
Created by
admin on Mon Mar 31 17:57:58 GMT 2025 , Edited by admin on Mon Mar 31 17:57:58 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID1045748
Created by
admin on Mon Mar 31 17:57:58 GMT 2025 , Edited by admin on Mon Mar 31 17:57:58 GMT 2025
|
PRIMARY | |||
|
300000055004
Created by
admin on Mon Mar 31 17:57:58 GMT 2025 , Edited by admin on Mon Mar 31 17:57:58 GMT 2025
|
PRIMARY | |||
|
C75126
Created by
admin on Mon Mar 31 17:57:58 GMT 2025 , Edited by admin on Mon Mar 31 17:57:58 GMT 2025
|
PRIMARY | |||
|
CHEMBL1097
Created by
admin on Mon Mar 31 17:57:58 GMT 2025 , Edited by admin on Mon Mar 31 17:57:58 GMT 2025
|
PRIMARY | |||
|
759312
Created by
admin on Mon Mar 31 17:57:58 GMT 2025 , Edited by admin on Mon Mar 31 17:57:58 GMT 2025
|
PRIMARY | |||
|
71417
Created by
admin on Mon Mar 31 17:57:58 GMT 2025 , Edited by admin on Mon Mar 31 17:57:58 GMT 2025
|
PRIMARY | |||
|
251-831-2
Created by
admin on Mon Mar 31 17:57:58 GMT 2025 , Edited by admin on Mon Mar 31 17:57:58 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |